antibodies to tirzepatide DACs (degrader–antibody conjugates) combine catalytic protein degraders with mAb-mediated delivery specific cell populations. This modality has the potential to improve tolerability and expand the therapeutic window relative to both cytotoxic ADCs In vivo antibody-selective conjugation technology
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16





























